01.03.2003 | Original Papers
Cost-utility of interferon β1b in the treatment of patients with active relapsing-remitting or secondary progressive multiple sclerosis
Erschienen in: The European Journal of Health Economics | Ausgabe 1/2003
Einloggen, um Zugang zu erhalten